Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05508191
Other study ID # 22-08-0682
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 17, 2022
Est. completion date December 31, 2022

Study information

Verified date February 2023
Source Indonesia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evidences regarding the effectiveness of adipose-derived mesenchymal stem cells (ADMSCs) secretome to alleviate skin aging have been extensively available, yet no studies hitherto directly investigated the best administration technique for such purpose. The objective of this study is to compare microneedling and fractional CO₂ laser methods in administrating ADMSCs secretome for facial skin rejuvenation of Indonesian adult women.


Description:

A single-blind, randomized clinical trial will be conducted upon thirty females (aged 35-59 years old) presented with signs of generalized facial cutaneous senescence. Their initial skin status will be evaluated utilizing dermoscopy photoaging scale (DPAS) and Janus-3® skin analyzer, along with skin capacitance using the Corneometer® and transepidermal water loss using the Tewameter®, followed by daily priming with 0.05% retinoic acid for two consecutive weeks. At second and fourth week, the participants are subjected to microneedle and fractional CO₂ laser according to the respective protocol in split-face fashion, which the randomization will be determined by a computer programme. Succeeding the treatment, four-fold concentrated ADMSCs secretome will be administered topically to the both sides of face. The final skin condition will ultimately be recorded at the sixth week, along with their satisfaction and convenience degree, the adverse events experienced during the trial, and subjective preference to the treatment. Appropriate statistical analyses will subsequently be performed at the significance level of 0.05.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 31, 2022
Est. primary completion date October 26, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 35 Years to 59 Years
Eligibility Inclusion Criteria: - Female, aged 35-59 years - Generalized wrinkles on the face - Consent for the 2-month clinical trial (4 times of follow-up with 2 weeks interval) Exclusion Criteria: - Prior history of hypertrophic scars or keloid formation - Prior history of allergy to topical anesthetic and/or retinoic acid cream - Prior history of autoimmune disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis, etc.) - Prior history of malignancies - Prior utilization of skincare products for the past 6 months - Currently under long-term immunosupressants medication (e.g. corticosteroids, biologic agents, cytostatics, etc.) Drop-out Criteria: - Pass away during the clinical trial - Refrain from the clinical trial before the trial completion - Absent for more than two days from the scheduled appointment - Suffer from coronavirus disease 2019 (COVID-19) at any time during the trial - Experience major adverse event(s) caused by topical products or treatments given in the clinical trial (e.g. allergic drug eruption or contact dermatitis). The participants will receive appropriate management if such event occurs.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Fractional CO2 Laser
Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. Half of the face will be irradiated with AMI? fractional CO2 laser according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
Microneedle
Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. The other half of the face will be treated with DrPen? dermapen according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.

Locations

Country Name City State
Indonesia Faculty of Medicine, Universitas Indonesia Jakarta Pusat DKI Jakarta

Sponsors (3)

Lead Sponsor Collaborator
Shannaz Nadia Yusharyahya Ministry of Education, Culture, Research, and Technology, Republic of Indonesia, PT. Kimia Farma (Persero) Tbk

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Skin aging changes evaluated by dermoscopy photoaging scale (DPAS) A thorough evaluation using dermoscope upon 11 parameters of skin aging (yellowish papules, solar elastosis, skin atrophy, lentigo, hypopigmented and hyperpigmented macules, telangiectasia, actinic keratosis, senile comedones, superficial wrinkles, deep wrinkles, and criss-cross wrinkles) observed on 4 locations (forehead, periorbita, zygoma, and mandible). Each finding on each location has a value of 1, so the maximum possible total score is 44.
*This is a numeric variable.
Week 0 (baseline), week 2 before intervention, week 4 before intervention, week 6 (end of trial)
Primary Skin aging changes evaluated by Janus-3? skin analyzer A comprehensive evaluation using Janus-3? skin analyzer upon 4 parameters of skin aging (wrinkle, pore size, pigmentation, and sebum) observed on the same location for each assessment. Each finding is expressed as percentage (%).
*This is a numeric variable.
Week 0 (baseline), week 2 before intervention, week 4 before intervention, week 6 (end of trial)
Primary Skin capacitance evaluated by the Corneometer? Total water content in the stratum corneum of the skin, reported in microsiemens.
*This is a numeric variable.
Week 0 (baseline), week 2 before intervention, week 4 before intervention, week 6 (end of trial)
Primary Transepidermal water loss evaluated by the Tewameter? Water evaporation rate in a given area of skin, reported in gram/m²/hour.
*This is a numeric variable.
Week 0 (baseline), week 2 before intervention, week 4 before intervention, week 6 (end of trial)
Secondary Likert scale for the satisfaction degree An interval of 0 (extremely unsatisfied) to 10 (extremely satisfied) for determination of the participants' satisfaction upon both treatments (microneedle and fractional CO2 laser).
*This is a numeric variable.
Week 6 (end of trial)
Secondary Visual analog scale (VAS) of pain for the convenience degree An interval of 0 (no pain whatsoever) to 10 (the most extreme pain possible) for determination of the participants' convenience during the trial with both treatments (microneedle and fractional CO2 laser).
*This is a numeric variable.
Week 6 (end of trial)
Secondary Number of adverse events experienced during the clinical trial Side effects experienced by the participants following the application of topical products (facial wash, sunscreen, anesthetic cream, and retinoic acid cream) and procedures (microneedle and fractional CO2 laser), such as erythema, warmth, itch, burning sensation, edema, peeled skin, and/or no adverse events, reported in frequency of each event. Each participant will be contacted one day after each treatment for side effect evaluation. They can also report any events experienced to the investigator at any time during the trial.
*This is a categorical variable.
Week 2 thirty minutes after intervention, week 4 thirty minutes after intervention, week 6 (end of trial)
Secondary Subjective preference to treatment Preference of each subject towards a particular treatment (microneedling or fractional CO2 laser) based on their experience during the trial
*This is a categorical variable
Week 6 (end of trial)
See also
  Status Clinical Trial Phase
Completed NCT04276753 - A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects N/A
Completed NCT06125912 - A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging N/A
Completed NCT02580370 - Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines Phase 3
Recruiting NCT01583478 - Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Phase 4
Completed NCT02003833 - Poly-L-lactic Acid for Skin Quality Phase 4
Completed NCT01447342 - A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines Phase 2/Phase 3
Completed NCT00986570 - Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face Phase 3
Completed NCT00974480 - Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging N/A
Completed NCT00272610 - Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin Phase 2
Recruiting NCT03730649 - Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure Early Phase 1
Completed NCT03312543 - Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles N/A
Active, not recruiting NCT05349799 - TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines N/A
Completed NCT03677258 - Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy N/A
Withdrawn NCT05854628 - The Role of Red Flavonoid in Photoaging N/A
Completed NCT01981980 - Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation N/A
Not yet recruiting NCT00767156 - Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging N/A
Recruiting NCT05813054 - Clinical Study to Evaluate the Anti-aging Efficacy of Dermial® N/A
Not yet recruiting NCT04485091 - TCA Peel and Photobiomodulation for Hand Rejuvenation Phase 2
Completed NCT05457491 - Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE) Phase 1
Completed NCT01237977 - Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines Phase 3